Thomas E. Stinchcombe

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations · Full text

Checkmate 063, Single-arm Trial, Medicine +8

Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer

Nasser K. Altorki, Xiaofei Wang, David Kozono et al. · New England Journal of Medicine · 2023 · 900 citations · Full text

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

Robert Z. Orlowski, Thomas E. Stinchcombe, Beverly S. Mitchell et al. · Journal of Clinical Oncology · 2002 · 760 citations

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian et al. · Journal of Clinical Oncology · 2017 · 580 citations

Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

Kyle Wang, Michael J. Eblan, Allison M. Deal et al. · Journal of Clinical Oncology · 2017 · 419 citations · Full text

Heart Failure, Dose-escalation Trials, Cardiovascular Toxicity +17